|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
TYPE OF REPORT | 8. Year | 2014 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Brent DelMonte, Vice President for Federal Government Relations |
Date | 07/21/2014 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Funding for USDA
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Review and Labeling of Food Derived From Biotechnology
H.R. 4432: Safe and Accurate Food Labeling Act
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
EPA Regulations on Agricultural Biotechnology
Efficient Science-Based Review of Biotech Products
Department of Interior, Environment, and Related Agencies Appropriations Act for FY 2015
Genetically Engineered (GE) Animals
Labeling
FDA Approval
GE Animal Models of Human Disease
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Amendment to Restrict FDA Approval of GE Salmon
Amendment on GE Salmon Labeling
Foreign Agricultural Biotechnology Laws and Regulations
Asynchrony of International Approvals
China Biotechnology Regulations
USDA/APHIS Agricultural Biotechnology Regulations
Coexistence of Production Systems
Efficient Science-Based Review of Biotech Products
Agriculture, Rural Development, FDA and Related Agencies Appropriations Act for FY 2015
Transatlantic Trade and Investment Partnership
Ag-Biotech Issues
TransPacific Partnership
Sanitary and Phytosanitary Issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Funding for Biomass Crop Assistance Program
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), Natl Security Council (NSC), Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
David |
Edwards |
|
|
|
Tracey |
LaTurner |
|
|
|
Dana |
O'Brien |
|
|
|
Matthew |
O'Mara |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Genetically Engineered (GE) Animal
Labeling
FDA Approval
GE Animal Models of Human Disease
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Amendment to Restrict FDA Approval of GE Salmon
Amendment on GE Salmon Labeling
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracey |
LaTurner |
|
|
|
Dana |
O'Brien |
|
|
|
David |
Edwards |
|
|
|
Brent |
DelMonte |
|
|
|
Cathleen |
Enright |
|
|
|
. |
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for FDA
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Funding for USDA
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
Funding for Centers for Disease Control and Prevention Vaccine Programs
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
Funding for National Institutes of Health
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
Funding for Biomass Crop Assistance Program
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Sequestration of PDUFA Fees
HR 2725: Food and Drug Administration Safety over Sequestration Act of 2013
S. 1413: FDA User Fee Protection Act
Agriculture, Rural Development, FDA and Related Agencies Appropriations Act for FY 2015
Energy Basic Research Funding
Energy and Water Development and Related Agencies Appropriations Act for FY 2015
Funding for Renewable Chemicals/Bio-based Products
Energy and Water Development and Related Agencies Appropriations Act for FY 2015
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Expansion of Biorefinery Assistance Program to Renewable Chemicals and Bio-based Products
Funding for Biofuels
Department of Defense Funding of Advanced Biofuels
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Department of Defense Appropriations Act for FY 2015
Department of Interior, Environment, and Related Agencies Appropriations for FY 2015
Energy and Water Development and Related Agencies Appropriations Act for FY 2015
Funding for Biorefineries
Department of Defense Funding of Advanced Biofuels
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Energy and Water Development and Related Agencies Appropriations Act for FY 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Security Council (NSC), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracey |
LaTurner |
|
|
|
Matthew |
Carr |
|
|
|
Cartier |
Esham |
|
|
|
Andrew |
Emmett |
|
|
|
Catharine |
Harris |
|
|
|
Brent |
DelMonte |
|
|
|
Derrick |
White |
|
|
|
Sara |
Radcliffe |
|
|
|
Erick |
Lutt |
|
|
|
Kelly |
Cappio |
|
|
|
Rina |
Singh |
|
|
|
Phyllis |
Arthur |
|
|
|
Matthew |
Schumaker |
|
|
|
Dana |
O'Brien |
|
|
|
Jeanne |
Haggerty |
|
|
|
Anna |
Weinstein |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
TransPacific Partnership
Data and Intellectual Property Protections for Pharmaceuticals
Patent Reform
H.R. 3309: Innovation Act of 2013
S. 1013: Patent Abuse Reduction Act of 2013
S. 1720: Patent Transparency and Improvements Act of 2013
S. 866: Patent Quality Improvement Act of 2013
Targeting Rogue and Opaque Letters (TROL) Act of 2014 (Discussion Draft)
FTC Regulation of Patent Demand Letters (Senate Commerce Committee Discussion Draft)
Drug Repurposing
H.R. 4287/S.2150: Independent Innovator and Repurposing Act
Intellectual Property International Enforcement
Compulsory Licensing
India Issues
Transatlantic Trade and Investment Partnership
Intellectual Property Issues
Patenting of Biological Inventions
DNA Patenting and Licensing
International Trade Commission Reform
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Catharine |
Harris |
|
|
|
Hans |
Sauer |
|
|
|
Jeanne |
Haggerty |
|
|
|
Brent |
Del Monte |
|
|
|
Tom |
DiLenge |
|
|
|
Joseph |
Damond |
|
|
|
Charles |
Fritts |
|
|
|
Anna |
Weinstein |
|
|
|
Derrick |
White |
|
|
|
Matthew |
Schumaker |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Genetically Engineered (GE) Animals
Labeling
GE Animal Models of Human Disease
FDA Approval
Agriculture, Rural Development, FDA and Related Agencies Appropriations Act for FY 2015
Amendment on GE Salmon Labeling
Amendment to Restrict FDA Approval of GE Salmon
Drug Importation
H.R. 4660: Commerce, Justice, Science and Related Agencies Appropriations Act for FY 2015
Review and Labeling of Food Derived From Biotechnology
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
H.R. 4432: Safe and Accurate Food Labeling Act
Funding for FDA
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Drug Evaluation and Review
Implementation of the FDA Safety and Innovation Act
21st Century Cures Initiative
Compassionate Use/Expanded Access
FDA Proposed Rule on Changes to Drug Labeling
Special Medical Use/Limited Population Drugs
H.R. 4475: Compassionate Freedom of Choice Act
H.R. 2090: The Patient Choice Act
H.R. 3742: Antibiotic Development to Advance Patient Treatment Act of 2013
Biosimilars
Colombia Biologics Regulations
Naming
Implementation of Affordable Care Act
Interchangeability and Pharmacy Substitution
USDA/APHIS Agricultural Biotechnology Regulations
Coexistence of Production Systems
Efficient Science-Based Review of Biotech Products
Agriculture, Rural Development, FDA and Related Agencies Appropriations Act for FY 2015
Drug Manufacturing, Quality & Distribution
Implementation of H.R. 3204: The Drug Quality and Security Act
Compounding
Sunshine Act Implementation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
David |
Edwards |
|
|
|
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
|
Sara |
Radcliffe |
|
|
|
Jeanne |
Haggerty |
|
|
|
Derrick |
White |
|
|
|
Dana |
O'Brien |
|
|
|
Matthew |
Schumaker |
|
|
|
Tom |
DiLenge |
|
|
|
Brent |
DelMonte |
|
|
|
Matthew |
O'Mara |
|
|
|
Cartier |
Esham |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeffrey |
Peters |
|
|
|
Catharine |
Harris |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Funding for Biomass Crop Assistance Program
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Biofuels (Non-Funding)
Renewable Fuel Standard
Production Tax Credit Extension
Accelerated Depreciation Extension
H.R. 3758: Second Generation Biofuel Extension Act of 2013
Renewable Chemicals/Bio-based Products (Non-Funding)
Bonus Depreciation for Renewable Chemical Facilities
Implementation of the Agriculture Act of 2014
Expansion of Master Limited Partnerships to Renewable Chemicals
New Production Tax Credit for Renewable Chemicals
S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act
H.R. 2421: Renewable Chemicals Parity Act
H.R. 1696/S. 795: Master Limited Partnerships Parity Act
Biorefineries (Non-Funding)
Implementation of the Agriculture Act of 2014
Energy Basic Research Funding
Energy and Water Development and Related Agencies Appropriations Act for FY 2015
Funding for Renewable Chemicals/Bio-based Products
Energy and Water Development and Related Agencies Appropriations Act for FY 2015
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Expansion of Biorefinery Assistance Program to Renewable Chemicals and Bio-based Products
Funding for Biofuels
Department of Defense Funding of Advanced Biofuels
Department of Defense Appropriations Act for FY 2015
Energy and Water Development and Related Agencies Appropriations Act for FY 2015
Department of Interior, Environment, and Related Agencies Appropriations for FY 2015
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Funding for Biorefineries
Department of Defense Funding of Advanced Biofuels
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Energy and Water Development and Related Agencies Appropriations Act for FY 2015
Toxic Substances Control Act Reform
Polloution Prevention Credit for Renewable Chemicals and Bio-based Products
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Economic Council (NEC), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Carr |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Charles |
Fritts |
|
|
|
Rina |
Singh |
|
|
|
Brent |
Del Monte |
|
|
|
Erick |
Lutt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Genetically Engineered (GE) Animals
Labeling
GE Animal Models of Human Disease
FDA Approval
Agriculture, Rural Development, FDA and Related Agencies Appropriations Act for FY 2015
Amendment on GE Salmon Labeling
Amendment to Restrict FDA Approval of GE Salmon
Review and Labeling of Food Derived From Biotechnology
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
H.R. 4432: Safe and Accurate Food Labeling Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
David |
Edwards |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
|
Matthew |
O'Mara |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Funding for Biomass Crop Assistance Program
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Biofuels (Non-Funding)
Renewable Fuel Standard
Production Tax Credit Extension
Accelerated Depreciation Extension
H.R. 3758: Second Generation Biofuel Extension Act of 2013
Renewable Chemicals/Bio-based Products (Non-Funding)
Bonus Depreciation for Renewable Chemical Facilities
Implementation of the Agriculture Act of 2014
Expansion of Master Limited Partnerships to Renewable Chemicals
New Production Tax Credit for Renewable Chemicals
S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act
H.R. 2421: Renewable Chemicals Parity Act
H.R. 1696/S. 795: Master Limited Partnerships Parity Act
Biorefineries (Non-Funding)
Implementation of the Agriculture Act of 2014
Energy Basic Research Funding
Energy and Water Development and Related Agencies Appropriations Act for FY 2015
Funding for Renewable Chemicals/Bio-based Products
Energy and Water Development and Related Agencies Appropriations Act for FY 2015
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Expansion of Biorefinery Assistance Program to Renewable Chemicals and Bio-based Products
Funding for Biofuels
Department of Defense Funding of Advanced Biofuels
Department of Defense Appropriations Act for FY 2015
Energy and Water Development and Related Agencies Appropriations Act for FY 2015
Department of Interior, Environment, and Related Agencies Appropriations for FY 2015
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Funding for Biorefineries
Department of Defense Funding of Advanced Biofuels
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Energy and Water Development and Related Agencies Appropriations Act for FY 2015
Toxic Substances Control Act Reform
Polloution Prevention Credit for Renewable Chemicals and Bio-based Products
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Economic Council (NEC), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Carr |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Charles |
Fritts |
|
|
|
Rina |
Singh |
|
|
|
Brent |
DelMonte |
|
|
|
Erick |
Lutt |
|
|
|
. |
. |
|
|
|
. |
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Funding for National Institutes of Health
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
Biosimilars
Colombia Biologics Regulations
Naming
Implementation of Affordable Care Act
Interchangeability and Pharmacy Substitution
Funding for Centers for Disease Control and Prevention Vaccine Programs
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
Vaccine Access/Financing
Adult Immunization (Senate Discussion Draft)
340B Drug Pricing Program
Implementation of Affordable Care Act
Program Implementation & Oversight
Departments of Labor, HHS, Education and Related Agencies Appropriations Act for FY 2015
Drug Importation
H.R. 4660: Commerce, Justice, Science and Related Agencies Appropriations Act for FY 2015
Funding for FDA
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Independent Payment Advisory Board
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
Reimbursement for Innovative Products
Medicare Part B Physician-Administered Products
Medicare Part D Prescription Drug Program
Medicaid Pricing and Rebates
Implementation of Affordable Care Act
H.R. 1416: The Cancer Patient Protection Act of 2013
National Center for Advancing Translational Science (NCATS) (Non-Funding)
Program Implementation
Sequestration of PDUFA Fees
Agriculture, Rural Development, FDA and Related Agencies Appropriations Act for FY 2015
HR 2725: Food and Drug Administration Safety Over Sequestration Act of 2013
S. 1413: FDA User Fee Protection Act
TransPacific Partnership
Regulatory Transparency
Data and Intellectual Property Protections for Pharmaceuticals
Transatlantic Trade & Investment Partnership
Regulatory Harmonization/Transparency
Drug Evaluation and Review
Implementation of the FDA Safety and Innovation Act
21st Century Cures Initiative
Compassionate Use/Expanded Access
FDA Proposed Rule on Changes to Drug Labeling
Special Medical Use/Limited Population Drugs
H.R. 4475: Compassionate Freedom of Choice Act
H.R. 2090: The Patient Choice Act
H.R. 3742: Antibiotic Development to Advance Patient Treatment Act of 2013
Orphan Drug Act Tax Credit
Clinical Trial Data Sharing and Disclosure
EU Policies
Drug Manufacturing, Quality & Distribution
Implementation of H.R. 3204: The Drug Quality and Security Act
Compounding
Sunshine Act Implementation
Medicare Physician Payment Sustainable Growth Rate Formula
S. 2110: Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014
Drug Repurposing
H.R. 4287/S.2150: Independent Innovator and Repurposing Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), U.S. Trade Representative (USTR), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Catharine |
Harris |
|
|
|
Andrew |
Emmett |
|
|
|
Charles |
Fritts |
|
|
|
Matthew |
Schumaker |
|
|
|
Jeanne |
Haggerty |
|
|
|
Sara |
Radcliffe |
|
|
|
Phyllis |
Arthur |
|
|
|
Anna |
Weinstein |
|
|
|
Derrick |
White |
|
|
|
Tom |
DiLenge |
|
|
|
Tracey |
LaTurner |
|
|
|
Laurel |
Todd |
|
|
|
Kelly |
Cappio |
|
|
|
Brent |
DelMonte |
|
|
|
Cartier |
Esham |
|
|
|
Jeffrey |
Peters |
|
|
|
Charles |
Crain |
|
|
|
Shelly |
Mui-Lipnik |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Security Council (NSC), Office of Management & Budget (OMB),
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sara |
Radcliffe |
|
|
|
Phyllis |
Arthur |
|
|
|
Tracey |
LaTurner |
|
|
|
Kelly |
Cappio |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Funding for National Institutes of Health
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
National Center for Advancing Translational Science (NCATS) (Non-Funding)
Program Implementation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sara |
Radcliffe |
|
|
|
Cartier |
Esham |
|
|
|
Kelly |
Cappio |
|
|
|
Phyllis |
Arthur |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
DelMonte |
|
|
|
Jeanne |
Haggerty |
|
|
|
Matthew |
Schumaker |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare Physician Payment Sustainable Growth Rate Formula
S. 2110: Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014
Independent Payment Advisory Board
Reimbursement for Innovative Products
Medicare Part B Physician-Administered Products
Medicare Part D Prescription Drug Program
Medicaid Pricing and Rebates
Implementation of Affordable Care Act
H.R. 1416: The Cancer Patient Protection Act of 2013
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brent |
DelMonte |
|
|
|
Laurel |
Todd |
|
|
|
Matthew |
Schumaker |
|
|
|
Jeanne |
Haggerty |
|
|
|
Catharine |
Harris |
|
|
|
Anna |
Weinstein |
|
|
|
Derrick |
White |
|
|
|
Sara |
Radcliffe |
|
|
|
Jeffrey |
Peters |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Sarbanes Oxley Section 404 (b)
Mandatory Audit Firm Rotation
H.R. 1564/S. 1526: The Audit Integrity and Job Protection Act
Capital Formation Investment Incentives
Reform of Capital Gains Rules
Reform of Net Operating Loss Rules
Reform of Passive Loss Rules
H.R. 4855: The PARTNER Act
S. 1658: The Start-up Jobs and Innovation Act
The COMPETE Act (Senator Carper Discussion Draft)
House Ways & Means Committee Discussion Draft (Rep. Camp)
Reform of SEC Regulation D
Implementation of Jumpstart Our Business Start-ups (JOBS) Act
H.R. 4554: Restricted Securities Relief Act
H.R. 4570: Private Placement Improvement Act
Expansion of Exemption under SEC Regulation A
H.R. 4565: Start-up Capital Modernization Act
Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions
H.R. 2629: The Fostering Innovation Act
Small Business Innovation Research (SBIR) Program
XBRL Exemption for Small Public Companies
H.R. 4164: Small Company Disclosure Simplification Act
Stock Exchange Tick Size
H.R. 3448: The Small Cap Liquidity Reform Act
H.R. 1952: The Spread Pricing Liquidity Act
Capital Market Enhancements
H.R. 4568: Small Business Freedom to Grow Act
H.R. 4571: To direct the SEC to revise its rules so as to increase the threshold amount for
requiring issuers to provide certain disclosures relating to compensatory benefits plans
H.R. 3623: Improving Access to Capital for Emerging Growth Companies Act
H.R. 4569: Disclosure Modernization and Simplification Act
H.R. 4697: To require the SEC to revise the definition of a WKSI to reduce the worldwide market
value threshold under the definition
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Securities & Exchange Commission (SEC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Brent |
DelMonte |
|
|
|
Cartier |
Esham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Tax Reform
House Ways & Means Committee Discussion Draft (Rep. Camp)
Orphan Drug Act Tax Credit
Controlled Foreign Corporation Look-Through Rule Extension
Renewable Chemicals/Bio-based Products
Bonus Depreciation for Renewable Chemical Facilities
Expansion of Master Limited Partnerships to Renewable Chemicals
New Production Tax Credit for Renewable Chemicals
S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act
H.R. 1696/S. 795: Master Limited Partnerships Parity Act
Biofuels
Production Tax Credit Extension
Accelerated Depreciation Extension
H.R. 3758: Second Generation Biofuel Extension Act of 2013
Research & Development Tax Credit Reforms
Extension
Permanency
H.R.3757: The Igniting American Research Act
H.R. 4438: American Research & Competitiveness Act of 2014
H.R.119: To amend the Internal Revenue Code to make permanent the credit for increasing
research activities
The Start-up Innovation Credit Act (Senator Coons Discussion Draft)
The COMPETE Act (Senator Carper Discussion Draft)
Capital Formation Investment Incentives
Reform of Capital Gains Rules
Reform of Net Operating Loss Rules
Reform of Passive Loss Rules
H.R. 4855: The PARTNER Act
S. 1658: The Start-up Jobs and Innovation Act
The COMPETE Act (Senator Carper Discussion Draft)
House Ways & Means Committee Discussion Draft (Rep. Camp)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Economic Council (NEC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Carr |
|
|
|
Erick |
Lutt |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Tom |
DiLenge |
|
|
|
Rina |
Singh |
|
|
|
Charles |
Fritts |
|
|
|
Charles |
Crain |
|
|
|
Brent |
Del Monte |
|
|
|
Dana |
O'Brien |
|
|
|
Cartier |
Esham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Trade Promotion Authority
S.1900/H.R. 3830: Bipartisan Congressional Trade Priorities Act of 2014
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Drug Importation
H.R. 4660: Commerce, Justice, Science and Related Agencies Appropriations Act for FY 2015
Intellectual Property International Enforcement
Compulsory Licensing
India Issues
Foreign Agricultural Biotechnology Laws and Regulations
China Biotechnology Regulations
Asynchrony of International Approvals
TransPacific Partnership
Regulatory Transparency
Data and Intellectual Property Protections for Pharmaceuticals
Sanitary and Phytosantiary Issues
International Trade Commission Reform
Transatlantic Trade and Investment Partnership
Intellectual Property Issues
Ag-Biotech Issues
Regulatory Harmonization/Transparency
Biosimilars
Colombia Biologics Regulations
Clinical Trial Data Sharing and Disclosure
EU Policies
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Natl Security Council (NSC), Food & Drug Administration (FDA), Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
DiLenge |
|
|
|
Andrew |
Emmett |
|
|
|
Brent |
DelMonte |
|
|
|
Joseph |
Damond |
|
|
|
Jeanne |
Haggerty |
|
|
|
Charles |
Fritts |
|
|
|
Matthew |
O'Mara |
|
|
|
Dana |
O'Brien |
|
|
|
Anna |
Weinstein |
|
|
|
Hans |
Sauer |
|
|
|
Cathleen |
Enright |
|
|
|
Catharine |
Harris |
|
|
|
David |
Edwards |
|
|
|
Derrick |
White |
|
|
|
Tracy |
LaTurner |
|
|
|
Jeffrey |
Peters |
|
|
|
Matthew |
Schumaker |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: BIO maintains a list of all of its members on its website at http://bio.org/membership/index.asp
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |